Bull Market Won't B...
Health Care: Drugs
Regeneron Pharmaceuticals Inc. (REGN: NASDAQ)
$258.52 -5.12 | -1.94%
05/21/13 - 12:20 PM ET
Portfolios with REGN
- Portfolio NameUser Type
- ContributorTechnical Setups for the We...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- Contributor10 Companies That Prove Sto...
- ContributorDrugs Facing FDA Approval i...
- ContributorEarnings Short Squeeze Play...
- Contributor10 Stocks of Top-Performing...
- ContributorEarnings Short Squeeze Play...
- ContributorRelative Strength Trades fo...
- Contributor10 Stocks That Boosted Firs...
Latest REGN Headlines from TheStreet
- 5 Stocks Underperforming Today In The Drugs Industry 05.20.13 | 01:05 pm
- Regeneron Pharmaceuticals Inc. Stock Buy Recommendation Reiterated (REGN) 05.20.13 | 10:05 am
- Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggard 05.15.13 | 05:05 pm
- 3 Stocks Underperforming Today In The Drugs Industry 05.15.13 | 01:05 pm
- Cramer's 'Mad Money' Recap: Stick With What Works 05.14.13 | 08:05 pm
- Cramer's 6 Stocks in 60 Seconds: MNST CLX REGN KR MDRX PG (Update 1) 05.14.13 | 05:05 pm
- Cramer: Biotech Makes a Comeback 05.10.13 | 04:05 pm
- Regeneron Stock Hits New 52-Week High (REGN) 05.10.13 | 11:05 am
- Biotech Is Where the Bucks Are 05.09.13 | 06:05 am
- Regeneron Pharmaceuticals Inc. Stock Buy Recommendation Reiterated (REGN) 05.08.13 | 10:05 am
Press Releases for REGN
- BioMed Realty To Develop 297,000 Square Feet In New York Fully Leased To Regeneron Pharmaceuticals - PR Newswire 04.04.13 | 09:04 am
- Regeneron Named World's #1 Biopharmaceutical Employer In Science Magazine Annual Survey - PR Newswire 09.21.12 | 12:09 pm
- Sanofi And Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody - PR Newswire 07.20.12 | 01:07 am
- Sanofi And Regeneron Announce Publication Of Positive Phase 2 Results For Lipid-Lowering PCSK9 Antibody In The Lancet - PR Newswire 05.26.12 | 11:05 am
- Sanofi And Regeneron Announce Regulatory And Clinical Update For ZALTRAP® (aflibercept) - PR Newswire 04.05.12 | 01:04 am
- Sanofi And Regeneron Report Phase 2 Data For Potential First-in-Class Lipid-Lowering PCSK9 Antibody - PR Newswire 03.26.12 | 11:03 am
- Regeneron And Bayer Announce Approval Of EYLEA® (aflibercept) Injection For The Treatment Of Wet Age-Related Macular Degeneration In Australia - PR Newswire 03.08.12 | 04:03 am
- Two Year Results Of Phase 3 Studies With EYLEA⢠(aflibercept) Injection In Wet AMD Show Sustained Improvement In Visual Acuity - PR Newswire 12.05.11 | 02:12 am
- Regeneron And Bayer Initiate Phase 3 Clinical Program For The Treatment Of Wet Age-Related Macular Degeneration In China - PR Newswire 11.28.11 | 02:11 am
- Phase 3 Trial Of ZALTRAP⢠(aflibercept) In Advanced Prostate Cancer To Continue As Planned At Recommendation Of Independent Data Monitoring Committee - PR Newswire 07.07.11 | 07:07 am
Partner Headlines for REGN
- IBD 50 Stocks Delivering Strong Earnings, Sales Gains - Investor's Business Daily 05.17.13 | 06:05 pm
- Stocks End Mixed In Quiet Trade; Stratasys Leads 3D Rally - Investor's Business Daily 05.13.13 | 04:05 pm
- Short Interest in Vertex Rises, in Celgene Falls - Benzinga 05.11.13 | 10:05 am
- Regeneron's Eylea Drives Astounding Q1 Results - Investor's Business Daily 05.10.13 | 06:05 pm
- Leading Biotechs Act Well But Be Careful Not To Chase - Investor's Business Daily 05.06.13 | 06:05 pm
- Stocks Up In Afternoon; United Rentals Tops Buy Point - Investor's Business Daily 05.06.13 | 03:05 pm
- Cramer's Mad Money - 10 Things To Watch In The Week Ahead (5/3/13) - Seeking Alpha 05.05.13 | 06:05 am
- Market Close Report: NASDAQ Composite index closes at 3,378.63 up 38.01 points - NASDAQ 05.03.13 | 08:05 pm
- Some IBD 50 Stocks Break Out, Others Near Buy Points - Investor's Business Daily 05.03.13 | 06:05 pm
- Market Wrap for Friday, May 3: Stocks Jump on Strong Jobs Data - Benzinga 05.03.13 | 04:05 pm
